A study in diabetes patients has shown that tight blood glucose control with the drug gliclazide prolonged release, along with the standard therapy, protects patients from the most serious complications associated with this disease, the risks for vascular and kidney. This is evidenced by the advanced study, one of the most extensive clinical trials...